We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division


Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

Protein-Expression Changes Specific to Immunoglobulin G4-Related Disease Analyzed

By LabMedica International staff writers
Posted on 09 Sep 2021
Print article
Image: Immunohistochemical staining showing IgG4-positive plasma cells (white arrows) from a girl with sclerosing mesenteritis (Photo courtesy of King Saud bin Abdulaziz University for Health Sciences)
Image: Immunohistochemical staining showing IgG4-positive plasma cells (white arrows) from a girl with sclerosing mesenteritis (Photo courtesy of King Saud bin Abdulaziz University for Health Sciences)
Immunoglobulin 4 (IgG4)-related disease (IgG4-RD) is a lymphoproliferative disorder characterized by elevated serum IgG4 levels and infiltration of IgG4-positive plasma cells into the affected tissues.

The pathology of IgG4-related disease cannot be explained based only on the change in a single gene or a protein. Organs affected by this disease are distributed throughout the body, including the lacrimal/salivary glands, pancreas, retroperitoneum, and thyroid. The disease is referred to as Mikulicz disease, autoimmune pancreatitis, retroperitoneal fibrosis, and Riedel thyroiditis, depending on the affected tissues.

A large team of Immunologists and Hematologists at the Kanazawa Medical University (Uchinada-machi, Japan) obtained sera from patients with IgG4-related disease receiving treatments. All patients had serum IgG4 levels ≥135 mg/dL and tissue IgG4/IgG ratios ≥40%, thereby satisfying the diagnostic criteria for IgG4-related disease. The control serum samples were collected from 13 healthy male volunteers (54–64 years old, median age of 59 years old).

Serum proteins from patients with IgG4-related disease and healthy subjects were resolved using two-dimensional electrophoresis, silver-stained, and scanned. Alternatively, the proteins were labeled with Cy2, Cy3, and Cy5 before electrophoresis. The proteins, whose expression differed significantly between patients and healthy individuals, and between before and after steroid treatment, were identified and validated using enzyme-linked immunosorbent assays.

The team used enzyme-linked immunosorbent assay (ELISA) kits for detecting human alpha-1 antitrypsin (A1AT, Immunology Consultants Laboratory, Inc. (Portland, OR, USA), clusterin (BioVender Research and Diagnostic Products, Brno, Czech Republic), and leucine rich α-2-glycoprotein (LRG-1) (Immuno-Biological Laboratories Co., Ltd, Fujioka-Shi, Japan). Pretreatment of the serum samples with ProteoMiner and the serum proteins were processed using a ProteoMiner Small-Capacity Kit (Bio-Rad, Hercules, CA, USA).

The investigators reported that pre-treatment sera from patients with IgG4-related disease was characterized by increased levels of immunoglobulins such as IgG1, IgG4; inflammatory factors such as α-1 antitrypsin (A1AT); and proteins associated with immune system regulation such as clusterin and leucine-rich α-2-glycoprotein (LRG-1). The serum levels of A1AT, LRG-1 and clusterin, during treatment with prednisolone for up to 12 months revealed that LRG-1 levels were halved after one month of treatment, comparable to those in healthy subjects; LRG-1 levels remained normal until the end of treatment.

The authors concluded that A1AT, LRG-1, and clusterin could be involved in the pathogenesis of IgG4-related disease, and their serum levels could reflect the disease state. In particular, LRG-1 could serve as a novel biomarker for the diagnosis and treatment of IgG4-related disease. The study was published on August 25, 2021 in the journal Clinica Chimica Acta.

Related Links:
Kanazawa Medical University
Immunology Consultants Laboratory
BioVender Research and Diagnostic Products
Immuno-Biological Laboratories

Gold Supplier
Molecular & Immunoassay Diagnostic Analyzer
Randox Discovery
Next-Generation Sequencing Platform
Clear Dx
Gold Supplier
Liquid Handling Workstation
AdvanSure E3 SYSTEM
Gold Supplier
SARS-CoV-2 Multiplex Real-Time RT-PCR Assay
GSD NovaPrime Plus SARS-CoV-2

Print article



view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more


view channel

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.